- Read Article
A meta-analysis of trials using biologics [adalimumab (ADA), ustekinumab (UST) and secukinumab (SEC)] in the the management of hidradenitis suppurativa (HS) suggests promising results, but more controlled, rigorous studies are needed.
While only adalimumab is currently FDA approved for this inflammatory skin disorder, numerous trials with other biologics exist or are in progress.
The Health and Human Services Notice of Benefit and Payment Parameters proposed rule for 2024 does not revise policies related to copay assistance and patient deductibles.Read Article
JAK inhibitors are approved for several immune-mediated inflammatory diseases and carry a higher than usual risk of herpes zoster in certain conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.Read Article
An estimated 100,000 to 120,000 fragility fractures occur annually in the Netherlands, the equivalent of at least 11 broken bones per hour. The cause is osteoporosis, a disease in which the skeleton becomes weak and fragile, leading to potentially devastating fractures that result in disability, loss of independence and premature death for some sufferers.Read Article